Pfizer’s Nyvepria (pegfilgrastim-apgf) biosimilar is now available in the US, according to a leading investment bank, despite ongoing patent infringement litigation initiated by Neulasta (pegfilgrastim) sponsor Amgen.
Nyvepria was the fourth biosimilar Neulasta pre-filled syringe product approved by the US Food and Drug Administration in June last...






